Weight Loss Drug Profiles
Profiles of every major weight loss drug we track.
Profiles of every major weight loss drug we track — approved, investigational, and next-gen. Grouped by mechanism so you can see the class lineage at a glance.
Related topic hubs
- Compare — Head-to-head comparisons
- GLP-1 Guide — How the class works
- Retatrutide — The headline drug
Drug profile pages
Each drug has a dedicated profile page — mechanism, trials, every comparison involving it, and safety context in one place.
- TirzepatideZepbound, Mounjaro
- SemaglutideWegovy, Ozempic
- Orforglipron (Foundayo)Foundayo
- CagriSemacagrilintide + semaglutide
- Cagrilintide
- Mazdutide (Xinermei)Xinermei
- SurvodutideBI 456906
- Amycretin (zenagamtide)zenagamtide
- PemvidutideALT-801
Drug landscape (early 2026)
| Drug | Sponsor | Mechanism | Peak loss | US status |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1 + GIP + glucagon | ~28.7% | Phase 3 |
| Tirzepatide (Zepbound/Mounjaro) | Eli Lilly | GLP-1 + GIP | ~21–23% | Approved |
| Semaglutide (Wegovy/Ozempic) | Novo Nordisk | GLP-1 | ~15–17% | Approved |
| Foundayo (orforglipron) | Eli Lilly | GLP-1 (small-molecule, oral) | ~12.4% | Approved Apr 2026 |
| CagriSema | Novo Nordisk | GLP-1 + amylin | ~20.4% | NDA filed Dec 2025 |
| Cagrilintide | Novo Nordisk | Amylin only | ~11.5% | Phase 3 |
| Survodutide | Boehringer / Zealand | GLP-1 + glucagon | ~18.7% | Phase 3 |
| Mazdutide (Xinermei) | Innovent | GLP-1 + glucagon | ~14–18% | Approved in China; US Phase 2 |
| Pemvidutide | Altimmune | GLP-1 + glucagon (1:1) | ~15.6% | Phase 2; Breakthrough for MASH |
| Amycretin (zenagamtide) | Novo Nordisk | GLP-1 + amylin (unimolecular) | ~22% subq / ~13% oral | Phase 3 |
Peak loss values are from the highest-dose, longest-duration published trial for each drug. Percentages are approximate and not directly comparable across trials of different duration.
Grouped by mechanism
- Triple agonist (GLP-1 + GIP + glucagon) — retatrutide. The class alone.
- Dual agonist, GLP-1 + GIP — tirzepatide.
- Dual agonist, GLP-1 + glucagon — survodutide, mazdutide, pemvidutide.
- GLP-1 + amylin combinations — CagriSema (two molecules), amycretin (single molecule).
- GLP-1 only — semaglutide, liraglutide, orforglipron (oral small molecule), exenatide, dulaglutide.
- Amylin only — cagrilintide, eloralintide.
For head-to-head comparisons between any two drugs above, see comparisons. For the class-level explainer, see the GLP-1 guide.
All drugs articles
7 articles
What Is Amycretin? Novo Nordisk's Oral GLP-1/Amylin Weight Loss Drug
Novo Nordisk's first-in-class GLP-1/amylin dual agonist — 13.1% weight loss as a daily pill in 12 weeks, 22% as a weekly injection in 36 weeks.
Updated March 2026
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Novo Nordisk's long-acting amylin analog — 11.5% weight loss as monotherapy, and the key ingredient in CagriSema.
Updated February 2026
What Is CagriSema? Novo Nordisk's Amylin + GLP-1 Weight Loss Combination
Novo Nordisk's amylin + GLP-1 combination — 20.4% weight loss in REDEFINE 1, NDA filed December 2025.
Updated February 2026
What Is Foundayo (Orforglipron)? Lilly's FDA-Approved Oral GLP-1 Weight Loss Pill
Eli Lilly's FDA-approved oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Starting at $149/month.
Updated April 2026
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China
The first GLP-1/glucagon dual agonist approved anywhere — how it works, what the trials show, and why it matters for the obesity drug landscape.
Updated February 2026
What Is Pemvidutide? Altimmune's GLP-1/Glucagon Dual Agonist for Weight Loss and MASH
Altimmune's balanced GLP-1/glucagon dual agonist — 15.6% weight loss, 54.7% liver fat reduction, FDA Breakthrough Therapy Designation for MASH.
Updated March 2026
What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH
Boehringer Ingelheim's dual GLP-1/glucagon agonist — 18.7% weight loss in Phase 2, 83% MASH resolution, Phase 3 ongoing.
Updated February 2026